Home › Funds › Deltroit Asset Management (UK) LLP › ABUS
Deltroit Asset Management (UK) LLP position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
Deltroit Asset Management (UK) LLP reported holding 1,200,000 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q2 2026 13F filing — a position valued at US$5.8M, representing 0.89% of its reported portfolio and ranking #24 among its reported holdings. Deltroit Asset Management (UK) LLP has disclosed ABUS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Deltroit Asset Management (UK) LLP's ABUS position evolved
Deltroit Asset Management (UK) LLP first disclosed a stake in ABUS in Q1 2026 at 800,000 shares (US$3.6M). The position peaked in Q2 2026 at 1,200,000 shares, worth US$5.8M. Across 2 filings, Deltroit Asset Management (UK) LLP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,200,000 shares valued at US$5.8M — an increase of 400,000 shares quarter over quarter.. Notable position changes include a 50% increase in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 800.00K | $3.60M | New |
| Q2 2026 | 1.20M | $5.76M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABUS and 13F data
ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 43 other funds we track also report a position in ABUS — the largest reported positions include Whitefort Capital Management, LP (US$75.8M), Two Seas Capital LP (US$38.9M), BlackBarn Capital Partners LP (US$12.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABUS
- Whitefort Capital Management, LP 15.79M sh · $75.81M · Q2 2026
- Two Seas Capital LP 8.14M sh · $38.93M · Q3 2026
- BlackBarn Capital Partners LP 2.50M sh · $12.00M · Q2 2026
- Western Standard LLC 542.79K sh · $2.61M · Q2 2026
- Rangeley Capital, LLC 500.00K sh · $2.40M · Q2 2026
More on Deltroit Asset Management (UK) LLP
FAQ
How long has Deltroit Asset Management (UK) LLP held ABUS?
Deltroit Asset Management (UK) LLP has disclosed ABUS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Deltroit Asset Management (UK) LLP's current position in ABUS?
As of Q2 2026, Deltroit Asset Management (UK) LLP holds 1.20M shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $5.76M, representing 0.89% of its reported portfolio and ranking #24.
Has Deltroit Asset Management (UK) LLP been buying or selling ABUS?
In the latest 13F filing (Q2 2026), Deltroit Asset Management (UK) LLP increased its position in ABUS. The position peaked in Q2 2026 at 1.20M shares.
Which other funds hold ABUS?
Other major institutional holders of ABUS include Whitefort Capital Management, LP, Two Seas Capital LP, BlackBarn Capital Partners LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.